{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:06:25Z","timestamp":1760983585285},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.euroneuro.2010.05.002","type":"journal-article","created":{"date-parts":[[2010,6,4]],"date-time":"2010-06-04T08:32:39Z","timestamp":1275640359000},"page":"688-694","source":"Crossref","is-referenced-by-count":13,"title":["Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians"],"prefix":"10.1016","volume":"20","author":[{"given":"Renan P.","family":"Souza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabilah I.","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew K.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aristotle N.","family":"Voineskos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert Y.","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2010.05.002_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","article-title":"Haploview: analysis and visualization of LD and haplotype maps","volume":"21","author":"Barrett","year":"2005","journal-title":"Bioinformatics"},{"key":"10.1016\/j.euroneuro.2010.05.002_bib2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1146\/annurev.pharmtox.011008.145634","article-title":"Akt\/GSK3 signaling in the action of psychotropic drugs","volume":"49","author":"Beaulieu","year":"2009","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.euroneuro.2010.05.002_bib3","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.318.7183.600a","article-title":"Multiple test procedures other than Bonferroni's deserve wider use","volume":"318","author":"Bender","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2010.05.002_bib4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pneurobio.2006.07.006","article-title":"The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways","volume":"79","author":"Beurel","year":"2006","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.euroneuro.2010.05.002_bib5","doi-asserted-by":"crossref","first-page":"33791","DOI":"10.1074\/jbc.M204861200","article-title":"Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation","volume":"277","author":"Carmichael","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.euroneuro.2010.05.002_bib6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/gepi.10252","article-title":"Pedigree disequilibrium tests for multilocus haplotypes","volume":"25","author":"Dudbridge","year":"2003","journal-title":"Genet. Epidemiol."},{"key":"10.1016\/j.euroneuro.2010.05.002_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/sim.973","article-title":"Sample size requirements for matched case\u2013control studies of gene\u2013environment interaction","volume":"21","author":"Gauderman","year":"2002","journal-title":"Stat. Med."},{"key":"10.1016\/j.euroneuro.2010.05.002_bib8","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archgenpsychiatry.2009.70","article-title":"Association of GSK3beta polymorphisms with brain structural changes in major depressive disorder","volume":"66","author":"Inkster","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2010.05.002_bib9","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2174\/1389450110607011421","article-title":"Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions","volume":"7","author":"Jope","year":"2006","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.euroneuro.2010.05.002_bib10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archpsyc.1982.04290040069010","article-title":"Tardive dyskinesia: prevalence and risk factors, 1959 to 1979","volume":"39","author":"Kane","year":"1982","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2010.05.002_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0014-5793(04)00082-1","article-title":"The effects of clozapine on the GSK-3-mediated signaling pathway","volume":"560","author":"Kang","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.euroneuro.2010.05.002_bib12","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/ana.20691","article-title":"GSK3B polymorphisms alter transcription and splicing in Parkinson's disease","volume":"58","author":"Kwok","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.euroneuro.2010.05.002_bib13","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1093\/nar\/19.19.5444","article-title":"A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies","volume":"19","author":"Lahiri","year":"1991","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.euroneuro.2010.05.002_bib14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/gepi.20410","article-title":"STrengthening the REporting of Genetic Association Studies (STREGA)\u2014an extension of the STROBE statement","volume":"33","author":"Little","year":"2009","journal-title":"Genet. Epidemiol."},{"key":"10.1016\/j.euroneuro.2010.05.002_bib15","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1086\/383251","article-title":"A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other","volume":"74","author":"Nyholt","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.euroneuro.2010.05.002_bib16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1440-1819.2009.01976.x","article-title":"Genetic association of BDNF val66met and GSK-3beta-50T\/C polymorphisms with tardive dyskinesia","volume":"63","author":"Park","year":"2009","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2010.05.002_bib17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/emm.2007.39","article-title":"Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex","volume":"39","author":"Roh","year":"2007","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.euroneuro.2010.05.002_bib18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archpsyc.1982.04290040080014","article-title":"Research diagnoses for tardive dyskinesia","volume":"39","author":"Schooler","year":"1982","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2010.05.002_bib19","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00213-010-1829-4","article-title":"Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia","volume":"210","author":"Souza","year":"2010","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.euroneuro.2010.05.002_bib20","doi-asserted-by":"crossref","DOI":"10.1097\/YIC.0b013e32833a5ff9","article-title":"Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia","author":"Souza","year":"2010","journal-title":"Int. Clin. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2010.05.002_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00213-008-1193-9","article-title":"Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response","volume":"200","author":"Souza","year":"2008","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.euroneuro.2010.05.002_bib22","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2217\/14622416.9.9.1285","article-title":"Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics","volume":"9","author":"Thelma","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.euroneuro.2010.05.002_bib23","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.neuropharm.2007.03.017","article-title":"Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity","volume":"52","author":"Wang","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2010.05.002_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0168-9525(01)02550-1","article-title":"Linkage disequilibrium and the mapping of complex human traits","volume":"18","author":"Weiss","year":"2002","journal-title":"Trends Genet."},{"key":"10.1016\/j.euroneuro.2010.05.002_bib25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.schres.2008.08.036","article-title":"Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia","volume":"106","author":"Zai","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2010.05.002_bib26","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/tpj.2009.2","article-title":"Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients","volume":"9","author":"Zai","year":"2009","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.euroneuro.2010.05.002_bib27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.euroneuro.2009.01.001","article-title":"Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia","volume":"19","author":"Zai","year":"2009","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X10000957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X10000957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T16:53:51Z","timestamp":1544460831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X10000957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0924977X10000957"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2010.05.002","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}